May 25th, 2022 (Earnings Report)Dear Reader,
HealthTechMovers.com just identified several healthtech stocks that are expected to release earnings starting today, January 26th.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
CVRx
Symbol: CVRX
Recent Price: $14.56
Average Analyst Price Target: $17.83 (22.46%)
Last Year's EPS: -$0.52
Consensus EPS Forecast: -$0.56
Expected Earnings Date: Jan 25 2023
Recent Analyst Action: Alexander Nowak, analyst at Craig-Hallum, reiterates coverage on CVRx (CVRX) in the Healthcare sector with a Buy rating and a price target of $ 18 (2 weeks ago).
Click for complete article >>--------------------------------------------------------------------------
Meridian Bioscience
Symbol: VIVO
Recent Price: $33.76
Average Analyst Price Target: $34.00 (0.71%)
Last Year's EPS: $0.35
Consensus EPS Forecast: $0.2
Expected Earnings Date: Jan 25 2023
Recent Analyst Action: Yi Chen, analyst at H.C. Wainwright, reiterates coverage on Meridian Bioscience (VIVO) in the Healthcare sector with a Hold rating and a price target of $ 34 (1 month ago).
Click for complete article >>--------------------------------------------------------------------------
Quipt Home Medical
Symbol: QIPT
Recent Price: $6.07
Average Analyst Price Target: $9.29 (52.83%)
Last Year's EPS: -$0.04
Consensus EPS Forecast: -$0.02
Expected Earnings Date: Jan 25 2023
Recent Analyst Action: Stefan Quenneville, analyst at Echelon Wealth Partners, reiterates coverage on Quipt Home Medical (QIPT) in the Healthcare sector with a Buy rating and a price target of $ 8.79 (2 weeks ago).
Click for complete article >>--------------------------------------------------------------------------
Resmed
Symbol: RMD
Recent Price: $233.62
Average Analyst Price Target: $259.67 (11.15%)
Last Year's EPS: $1.47
Consensus EPS Forecast: $1.6
Expected Earnings Date: Jan 25 2023
Recent Analyst Action: Michael Matson, analyst at Needham, reiterates coverage on Resmed (RMD) in the Healthcare sector with a Hold rating and has not provided a price target (5 days ago).
Click for complete article >>--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
